Effects of hypericin and a chlorin based photosensitizer alone or in combination in squamous cell carcinoma cells in the dark

Photodiagnosis and Photodynamic Therapy

Volumn 9, Issue 4, 2012, Pages 321-331

  Besic Gyenge, Emina ^a   Forny, Patrick ^a   Lüscher, Daniel ^a   Laass, Andrea ^a   Walt, Heinrich ^b   Maake, Caroline ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Dark toxicity; Head and neck cancer; Hypericin; MTHPC; Photodynamic therapy; Photosensitizer

Indexed keywords

FOSLIPOS; HYPERICIN; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CYTOTOXICITY; DNA DAMAGE; DRUG TUMOR LEVEL; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOCYTOCHEMISTRY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL;

CELL LINE, TUMOR; DARKNESS; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; HUMANS; LIPOSOMES; MESOPORPHYRINS; NEOPLASMS, SQUAMOUS CELL; PERYLENE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; RNA; TRANS-GOLGI NETWORK;

EID: 84870330394     PISSN: 15721000     EISSN: 18731597     Source Type: Journal    
DOI: 10.1016/j.pdpdt.2012.03.006     Document Type: Article

References (32)

1. Biel M.A. Photodynamic therapy of head and neck cancers. Methods Mol Biol 2010, 635:281-293.
2. Bredell M.G., Besic E., Maake C., et al. The application and challenges of clinical PD-PDT in the head and neck region: a short review. J Photochem Photobiol B 2010, 101(3):185-190.
3. O'Connor A.E., Gallagher W.M., Byrne A.T. Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy. Photochem Photobiol 2009, 85(5):1053-1074.
4. Prasad P.S., Schwartz S.D., Hubschman J.P. Age-related macular degeneration: current and novel therapies. Maturitas 2010, 66(1):46-50.
5. Ladner D.P., Steiner R.A., Allemann J., et al. Photodynamic diagnosis of breast tumours after oral application of aminolevulinic acid. Br J Cancer 2001, 84(1):33-37.
6. Ladner D.P., et al. Synergistic toxicity of delta-aminolaevulinic acid-induced protoporphyrin IX used for photodiagnosis and hypericum extract, a herbal antidepressant. Br J Dermatol 2001, 144(4):916-918.
7. Schneider-Yin X., Kurmanaviciene A., Roth M., et al. Hypericin and 5-aminolevulinic acid-induced protoporphyrin IX induce enhanced phototoxicity in human endometrial cancer cells with non-coherent white light. Photodiagnosis Photodyn Ther 2009, 6(1):12-18.
8. Lüthi M., Gyenge E.B., Engström M., et al. Hypericin- and mTHPC-mediated photodynamic therapy for the treatment of cariogenic bacteria. Med Laser Appl 2009, 24(4):227-236.
9. Dhawan A, et al. Protocol for the Single Cell Gel Electrophoresis/Comet Assay for Rapid Genotoxicity Assessment: Marg, India; p. 1-10, http://www.cometassayindia.org/Protocol%20for%20Comet%20Assay.PDF.
10. Berlanda J., Kiesslich T., Engelhardt V., et al. Comparative in vitro study on the characteristics of different photosensitizers employed in PDT. J Photochem Photobiol B 2010, 100(3):173-180.
11. Allison R.R., Downie G.H., Cuenca R., Hu X.-H., Childs C.J.H., Sibata C.H. Photosensitizers in clinical PDT. Photodiagn Photodyn Ther 2004, 1:27-42.
12. Kubin A., Wierrani F., Burner U., et al. Hypericin - the facts about a controversial agent. Curr Pharm Des 2005, 11(2):233-253.
13. Haimovitz-Friedman A., Balaban N., McLoughlin M., et al. Protein kinase C mediates basic fibroblast growth factor protection of endothelial cells against radiation-induced apoptosis. Cancer Res 1994, 54(10):2591-2597.
14. Kim C.Y., Giaccia A.J., Strulovici B., et al. Differential expression of protein kinase C epsilon protein in lung cancer cell lines by ionising radiation. Br J Cancer 1992, 66(5):844-849.
15. Vandenbogaerde A.L., Delaey E.M., Vantieghem A.M., et al. Cytotoxicity and antiproliferative effect of hypericin and derivatives after photosensitization. Photochem Photobiol 1998, 67(1):119-125.
16. Johnson S.A., Pardini R.S. Antioxidant enzyme response to hypericin in EMT6 mouse mammary carcinoma cells. Free Radic Biol Med 1998, 24(5):817-826.
17. Obach R.S. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000, 294(1):88-95.
18. Budzinski J.W., Foster B.C., Vandenhoek S., et al. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000, 7(4):273-282.
19. Sureau F., Miskovsky P., Chinsky L., Turpin P.Y. Hypericin-induced cell photosensitization involves an intracellular pH decrease. J Am Chem Soc 1996, 118(40):9484-9487.
20. Kiesslich T., Berlanda J., Plaetzer K., et al. Comparative characterization of the efficiency and cellular pharmacokinetics of Foscan- and Foslip-based photodynamic treatment in human biliary tract cancer cell lines. Photochem Photobiol Sci 2007, 6(6):619-627.
21. Ho Y.F., Wu M.H., Cheng B.H., et al. Lipid-mediated preferential localization of hypericin in lipid membranes. Biochim Biophys Acta 2009, 1788(6):1287-1295.
22. Kiesslich T., Neureiter D., Alinger B., et al. Uptake and phototoxicity of meso-tetrahydroxyphenyl chlorine are highly variable in human biliary tract cancer cell lines and correlate with markers of differentiation and proliferation. Photochem Photobiol Sci 2009, 9(5):734-743.
23. Ritz R., Muller M., Dietz K., et al. Hypericin uptake: a prognostic marker for survival in high-grade glioma. J Clin Neurosci 2008, 15(7):778-783.
24. Sevenants M.R. Pigments of blepharisma undulans compared with hypericin. J Protozool 1965, 12(2):240-245.
25. Martinez R.B.A.G. Photobleaching of sensitisers used in photodynamic therapy. Tetrahedron 2001, 57(591):9513-9547.
26. Bonnett R., Martinez G. Photobleaching of compounds of the 5,10,15,20-Tetrakis(m-hydroxyphenyl)porphyrin Series (m-THPP, m-THPC, and m-THPBC). Org Lett 2002, 4(12):2013-2016.
27. Bano G., Stanicova J., Jancura D., et al. On the diffusion of hypericin in dimethylsulfoxide/water mixtures-the effect of aggregation. J Phys Chem B 2011, 115(10):2417-2423.
28. Gyenge E.B., Hiestand S., Graefe S., et al. Cellular and molecular effects of the liposomal mTHPC derivative Foslipos in prostate carcinoma cells in vitro. Photodiagn Photodyn Ther 2011, 8(2):86-96.
29. Ma L., Moan J., Berg K. Evaluation of a new photosensitizer, meso-tetra-hydroxyphenyl-chlorin, for use in photodynamic therapy: a comparison of its photobiological properties with those of two other photosensitizers. Int J Cancer 1994, 57(6):883-888.
30. Ball D.J., Vernon D.I., Brown S.B. The high photoactivity of m-THPC in photodynamic therapy. Unusually strong retention of m-THPC by RIF-1 cells in culture. Photochem Photobiol 1999, 69(3):360-363.
31. Mitra S., Foster T.H. Photophysical parameters, photosensitizer retention and tissue optical properties completely account for the higher photodynamic efficacy of meso-tetra-hydroxyphenyl-chlorin vs Photofrin. Photochem Photobiol 2005, 81(4):849-859.
32. Theodossiou T.A., Hothersall J.S., De Witte P.A., et al. The multifaceted photocytotoxic profile of hypericin. Mol Pharm 2009, 6(6):1775-1789.